XILIO THERAPEUTICS INC (XLO) Stock Price, Quote, News and Overview
NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD
XLO Quote, Performance and Key Statistics
0.7398
-0.01 (-1.39%)
The current stock price of XLO is 0.7398 USD. In the past month the price increased by 8.84%. In the past year, price decreased by -37.31%.
XLO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.09 | 346.84B | ||
| AMGN | AMGEN INC | 13.49 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1724.79 | 128.59B | ||
| GILD | GILEAD SCIENCES INC | 13.28 | 128.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.62 | 65.17B | ||
| ARGX | ARGENX SE - ADR | 345.61 | 40.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.40B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 21.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.81B | ||
| BIIB | BIOGEN INC | 7.7 | 17.85B |
Related stock screener links
About XLO
Company Profile
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Company Info
XILIO THERAPEUTICS INC
828 Winter Street, Suite 300
Waltham MASSACHUSETTS US
Employees: 64
Phone: 16174304680
XILIO THERAPEUTICS INC / XLO FAQ
What is the stock price of XILIO THERAPEUTICS INC today?
The current stock price of XLO is 0.7398 USD. The price decreased by -1.39% in the last trading session.
What is the ticker symbol for XILIO THERAPEUTICS INC stock?
The exchange symbol of XILIO THERAPEUTICS INC is XLO and it is listed on the Nasdaq exchange.
On which exchange is XLO stock listed?
XLO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for XILIO THERAPEUTICS INC stock?
6 analysts have analysed XLO and the average price target is 4.08 USD. This implies a price increase of 451.5% is expected in the next year compared to the current price of 0.7398. Check the XILIO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is XILIO THERAPEUTICS INC worth?
XILIO THERAPEUTICS INC (XLO) has a market capitalization of 38.31M USD. This makes XLO a Nano Cap stock.
How many employees does XILIO THERAPEUTICS INC have?
XILIO THERAPEUTICS INC (XLO) currently has 64 employees.
What are the support and resistance levels for XILIO THERAPEUTICS INC (XLO) stock?
XILIO THERAPEUTICS INC (XLO) has a support level at 0.69 and a resistance level at 0.75. Check the full technical report for a detailed analysis of XLO support and resistance levels.
Is XILIO THERAPEUTICS INC (XLO) expected to grow?
The Revenue of XILIO THERAPEUTICS INC (XLO) is expected to grow by 527.19% in the next year. Check the estimates tab for more information on the XLO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy XILIO THERAPEUTICS INC (XLO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XLO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XLO, evaluating the profitability, health, valuation and growth aspects
- XILIO THERAPEUTICS INC (XLO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XILIO THERAPEUTICS INC (XLO) Sales and EPS estimates to see what analysts future expectations are.
- XILIO THERAPEUTICS INC (XLO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XILIO THERAPEUTICS INC (XLO) Insider and Institutional Ownership to learn about the owners and their transactions.
- XILIO THERAPEUTICS INC (XLO) Stock Chart to make your own analysis
- XILIO THERAPEUTICS INC (XLO) Latest news and press-releases to stay up to date.
Does XILIO THERAPEUTICS INC (XLO) stock pay dividends?
XLO does not pay a dividend.
When does XILIO THERAPEUTICS INC (XLO) report earnings?
XILIO THERAPEUTICS INC (XLO) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of XILIO THERAPEUTICS INC (XLO)?
XILIO THERAPEUTICS INC (XLO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is the Short Interest ratio of XILIO THERAPEUTICS INC (XLO) stock?
The outstanding short interest for XILIO THERAPEUTICS INC (XLO) is 1.51% of its float. Check the ownership tab for more information on the XLO short interest.
XLO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to XLO. When comparing the yearly performance of all stocks, XLO is a bad performer in the overall market: 73.01% of all stocks are doing better.
XLO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XLO. The financial health of XLO is average, but there are quite some concerns on its profitability.
XLO Financial Highlights
Over the last trailing twelve months XLO reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS increased by 53.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.94% | ||
| ROE | -330.95% | ||
| Debt/Equity | 0 |
XLO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to XLO. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 70.73% and a revenue growth 527.19% for XLO